68 completed, 28 active not recruiting, 24 recruiting, 15 unknown. 160 Phase 2, 33 Phase 1, 2 Phase 3.
Follow tremelimumab: new trials by email Literature Review of tremelimumab trials Research Report on tremelimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-10-01 | 2026-10-05 |
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2026-09-15 | 2026-08-06 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma RBS2418, STRIDE (durvalumab + tremelimumab) - Advanced Unresectable Hepatocellular Carcinoma | Phase 2 | Recruiting | Riboscience, LLC. | 220 | 2026-04-10 | 2026-04-24 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| IIT2025-03-YANG-LIFT-HCC STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA) - Hepato Cellular Carcinoma | Phase 2 | Recruiting | Ju Dong Yang | 41 | 2026-04-01 | 2026-03-27 |
| Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis Selective Internal Radiotherapy, Tremelimumab, Durvalumab - Hepatocellular Carcinoma Non-resectable | Phase 2 | Recruiting | Center Eugene Marquis | 80 | 2026-02-25 | 2026-05-05 |
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
| Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma Durvalumab Plus Tremelimumab, HAIC (GEMOX) - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Recruiting | UNICANCER | 196 | 2025-11-14 | 2026-02-03 |
| BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma BC3402, Durvalumab, Tremelimumab - Hepato Cellular Carcinoma (HCC) | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2025-11-01 | 2026-02-19 | |
| STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma STRIDE (durvalumab + tremelimumab), Durvalumab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 140 | 2025-10-21 | 2026-08-11 |
| A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma Radiation Therapy, Tremelimumab, Durvalumab - Hepatocellular Carcinoma (HCC) | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2025-10-01 | 2025-11-18 | |
| Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Durvalumab, Tremelimumab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | AstraZeneca | 114 | 2025-08-05 | 2026-10-13 |
| Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC Photon radiotherapy, Tremelimumab, Durvalumab - HCC - Hepatocellular Carcinoma, Tremelimumab | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 45 | 2025-05-22 | 2026-10-01 |
| Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC Proton radiotherapy, Tremelimumab, Durvalumab - HCC - Hepatocellular Carcinoma, Durvalumab | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 45 | 2025-05-22 | 2026-10-01 |
| Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Yoon Jun Kim | 24 | 2025-04-18 | 2025-05-14 |
| Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) Zanzalintinib, Durvalumab, Tremelimumab - Hepatocellular Carcinoma | Phase 2 | Recruiting | Anwaar Saeed | 40 | 2024-12-18 | 2025-11-06 |
| Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis Tremelimumab, Durvalumab - Hepatocellular Carcinoma, Cirrhosis, Liver | Phase 2 | Recruiting | The University of Texas Health Science Center at San Antonio | 32 | 2024-12-02 | 2026-01-06 |
| Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma Durvalumab, Tremelimumab, Gemcitabine - Borderline Resectable Carcinoma, Biliary Tract Cancer | Phase 2 | Withdrawn | Georgetown University | 2024-12-01 | 2024-11-12 |
Showing 20 of 160. Sign in to see all of them.
Carcinoma, Hepatocellular (29) · Carcinoma, Non-Small-Cell Lung (15) · Squamous Cell Carcinoma of Head and Neck (12) · Colorectal Neoplasms (11) · Biliary Tract Neoplasms (7) · Liver Neoplasms (7) · Melanoma (7) · Neoplasms (7) · Prostatic Neoplasms (7) · Urinary Bladder Neoplasms (7) · Breast Neoplasms (6) · Cholangiocarcinoma (6) · Adenocarcinoma Of Esophagus (5) · Diabetes Mellitus, Insulin-Dependent, 12 (5) · Lung Neoplasms (5)
AstraZeneca (13) · Canadian Cancer Trials Group (9) · National Cancer Institute (NCI) (8) · Memorial Sloan Kettering Cancer Center (5) · Jonsson Comprehensive Cancer Center (4) · M.D. Anderson Cancer Center (4) · MedImmune LLC (4) · Seoul National University Hospital (4) · Chang Gung Memorial Hospital (3) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (3) · Ludwig Institute for Cancer Research (3) · Samsung Medical Center (3) · UNICANCER (3) · Yonsei University (3) · AHS Cancer Control Alberta (2)
United States (76) · Canada (24) · France (18) · South Korea (18) · Spain (17) · Germany (16) · Italy (15) · United Kingdom (9) · Taiwan (7) · Australia (6) · Belgium (6) · Netherlands (5) · Hong Kong (4) · Hungary (3) · Israel (3)
Tim F Greten, M.D. (5) · Arndt Vogel, Prof. Dr. (2) · Jaume Capdevila, M.D., Ph.D. (2) · Michele Maio, MD (2) · Samuel Funt, MD (2) · Sebastien Hotte (2) · Aaron Hansen (1) · Abha Gupta (1) · Adel Kardosh (1) · Adrian Sacher, M.D. (1) · Ahmad Tarhini, MD (1) · Aiwu R He, MD (1)
PMID 18452610, PMID 20856802, PMID 21558401, PMID 24035405, PMID 24209604, PMID 25819643, PMID 26541610, PMID 27262113, PMID 27816492, PMID 28259287, PMID 28337197, PMID 28729154, PMID 28885881, PMID 28923358, PMID 29773326, PMID 29942666, PMID 30243800, PMID 30383184, PMID 30578687, PMID 30642290, PMID 30688989, PMID 30883000, PMID 31671191, PMID 32203306, PMID 32379280, PMID 32620213, PMID 32778095, PMID 33279854, PMID 33428583, PMID 33844995, PMID 33893692, PMID 34103352, PMID 34292792, PMID 34429332, PMID 34663638, PMID 34800700, PMID 35033226, PMID 35078923, PMID 35278356, PMID 35320892, PMID 35534690, PMID 35934010, PMID 36007218, PMID 36028483, PMID 36469573, PMID 36493574, PMID 36754451, PMID 36809050, PMID 37185961, PMID 37221181
2018 (7), 2017 (6), 2016 (4), 2015 (3), 2008 (2), 2023 (2), P30CA060553 (2), 2019 (1), P30CA015704 (1), P30CA033572 (1), P30CA138292 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186704 (1), UM1CA186709 (1)